

**VANCOUVER GENERAL HOSPITAL  
CSU PHARMACEUTICAL SCIENCES  
SPECIAL ACCESS DRUG DATA SHEET**

---

**DRUG NAME**

Quinupristin/dalfopristin

**ALTERNATE NAME**

Synercid® (PR 59500)

---

**MANUFACTURER**

Rhône-Poulenc Rorer

---

**STRENGTH**

500mg vials (150mg quinupristin/350mg dalfopristin)

**DOSAGE FORM**

IV injection

---

**INDICATIONS**

- Used primarily for patients with Gram-positive infections, including Methicillin Resistant Staph aureus (MRSA) and Vancomycin Resistant Enterococcus faecium, where alternative treatment options have failed or are contraindicated.

---

**DOSAGE AND ADMINISTRATION**

- 7.5mg (of combination)/kg IV q8-12h over 60 minutes
- Mix in D5W only
- Reconstitute each vial with 5mL of D5W to achieve a concentration of 100mg/mL. This solution is stable for 30 minutes.
- For central lines: minimum volume 100mL
- For peripheral IV: minimum volume 250mL
- Prepared IV bag is stable at room temperature for 5 hours and in the fridge for up to 54 hours
- If venous irritation occurs flush line with D5W solution for 60 minutes at a rate of 3mL/min or higher
- Volumes may be increased to 500-750mL to reduce venous irritation

---

**KNOWN SIDE EFFECTS\***

- Local reactions at the infusion site (pain, erythema, itching)
- Arthralgia, myalgia, diarrhea, headache, vomiting, rash, pruritus, pain and increases in liver enzymes have been reported.

---

**SPECIAL PRECAUTIONS**

- Compatible with D5W only.
- Flush infusion lines with D5W before heparin is injected.
- Do not use NS or heparin to flush infusion lines.
- Do not mix with other medications in the same infusion bag.
- Compatible via Y-site with the following medications when mixed in D5W: aztreonam, ciprofloxacin, haloperidol, metoclopramide and potassium chloride.

---

**\*REPORT ANY ADVERSE DRUG REACTIONS TO CSU PHARMACEUTICAL SCIENCES**

REV 06NOV2008